2025 Latin America Anti-Retroviral Drugs Revenue Opportunities Report
Description
The 2025 Latin America Anti-Retroviral Drugs Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Anti-Retroviral Drugs by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the antiretroviral (ARV) drugs market in Latin America are Gilead Sciences, ViiV Healthcare, Janssen Pharmaceuticals, and Merck & Co. Gilead Sciences is a dominant player in HIV therapeutics, investing in innovative drugs like lenacapavir, a twice-yearly injectable for HIV prevention approved by the FDA, which represents a significant advance in treatment and prevention. ViiV Healthcare, a joint venture among GlaxoSmithKline, Pfizer, and Shionogi, focuses on long-acting injectable cabotegravir and leverages voluntary licenses to facilitate access in low- and middle-income countries, including Latin America. Janssen Pharmaceuticals (Johnson & Johnson) extends the integrase inhibitor line with treatments tailored to diverse populations, and Merck co-develops once-weekly regimens to diversify options and address resistance issues.
In Latin America, these pharmaceutical companies face challenges such as uneven PrEP implementation, regulatory approvals, and access disparities. Brazil, Mexico, and Colombia lead regional progress, notably with Brazil reviewing cabotegravir approval, while many countries still lack access to long-acting injectables like cabotegravir or lenacapavir, despite their demonstrated efficacy. The HIV drugs market in South America is growing at a 6.2% CAGR, with multi-class combination drugs driving significant impact. These companies actively engage in partnerships, flexible pricing, and digital adherence support to expand treatment access, aiming to reduce HIV infections and improve outcomes in Latin America.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Anti-Retroviral Drugs by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the antiretroviral (ARV) drugs market in Latin America are Gilead Sciences, ViiV Healthcare, Janssen Pharmaceuticals, and Merck & Co. Gilead Sciences is a dominant player in HIV therapeutics, investing in innovative drugs like lenacapavir, a twice-yearly injectable for HIV prevention approved by the FDA, which represents a significant advance in treatment and prevention. ViiV Healthcare, a joint venture among GlaxoSmithKline, Pfizer, and Shionogi, focuses on long-acting injectable cabotegravir and leverages voluntary licenses to facilitate access in low- and middle-income countries, including Latin America. Janssen Pharmaceuticals (Johnson & Johnson) extends the integrase inhibitor line with treatments tailored to diverse populations, and Merck co-develops once-weekly regimens to diversify options and address resistance issues.
In Latin America, these pharmaceutical companies face challenges such as uneven PrEP implementation, regulatory approvals, and access disparities. Brazil, Mexico, and Colombia lead regional progress, notably with Brazil reviewing cabotegravir approval, while many countries still lack access to long-acting injectables like cabotegravir or lenacapavir, despite their demonstrated efficacy. The HIV drugs market in South America is growing at a 6.2% CAGR, with multi-class combination drugs driving significant impact. These companies actively engage in partnerships, flexible pricing, and digital adherence support to expand treatment access, aiming to reduce HIV infections and improve outcomes in Latin America.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
